放疗联合吡咯替尼治疗人表皮生长因子受体2阳性乳腺癌脑转移患者的效果及安全性  

Efficacy and safety of radiotherapy combined with pyrotinib in treatment of human epidermal growth factor receptor 2-positive breast cancer patients with brain metastasis

作　　者：王仙玲[1] 蒋倩[1] Wang Xianling;Jiang Qian(Department of Radiotherapy,Shanxi Province Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院、中国医学科学院肿瘤医院山西医院、山西医科大学附属肿瘤医院放疗科,太原030013

出　　处：《肿瘤研究与临床》2024年第8期622-625,共4页Cancer Research and Clinic

摘　　要：目的探讨放疗联合吡咯替尼治疗人表皮生长因子受体2(HER2)阳性乳腺癌脑转移患者的效果及安全性。方法回顾性队列研究。回顾性分析2021年1月至2023年1月山西省肿瘤医院收治的36例HER2阳性乳腺癌脑转移患者的临床资料,根据治疗方法的不同将患者分为观察组与对照组,每组18例。对照组采用单纯放疗,观察组采用放疗联合吡咯替尼治疗。比较两组的客观缓解率、疾病控制率、不良反应发生情况;采用Kaplan-Meier法进行生存分析。结果所有患者均为女性;既往均接受曲妥珠单抗或曲妥珠单抗联合帕妥珠单抗辅助或新辅助治疗。观察组的客观缓解率及疾病控制率均高于对照组[83.33%(15/18)比50.00%(9/18),94.44%(17/18)比66.67%(12/18)],差异均有统计学意义(χ^(2)=4.71,P=0.034;χ^(2)=4.43,P=0.034)。观察组腹泻发生率高于对照组[55.56%(10/18)比16.67%(3/18),P=0.035],而两组恶心、疲劳、口腔炎发生率差异均无统计学意义(均P=1.000)。观察组、对照组中位无进展生存时间分别为14.38、12.08个月,两组无进展生存比较差异有统计学意义(P=0.040);观察组、对照组中位总生存时间分别为15.78、11.19个月,两组总生存比较差异有统计学意义(P=0.034)。结论放疗联合吡咯替尼治疗HER2阳性乳腺癌脑转移效果较好,无严重不良反应,且能延长患者的生存时间。ObjectiveTo investigate the clinical efficacy and safety of radiotherapy combined with pyrotinib for human epidermal growth factor receptor 2(HER2)-positive breast cancer patients with brain metastasis.MethodsA retrospective cohort study was conducted.The clinical data of 36 HER2-positive breast cancer patients with brain metastasis admitted to Shanxi Province Cancer Hospital from January 2021 to January 2023 were retrospectively analyzed.According to the different treatment methods,the patients were divided into the observation group and the control group,18 cases in each group.The control group was treated with radiotherapy alone,and the observation group was treated with radiotherapy combined with pyrotinib.The objective remission rate,the disease control rate and the incidence of adverse reactions of both groups were compared;Kaplan-Meier method was used for survival analysis.ResultsAll patients were female and received trastuzumab or trastuzumab combined with pertuzumab chemotherapy or neoadjuvant therapy.The objective response rate of and disease control rate of in the observation group were higher than those in the control group[83.33%(15/18)vs.50.00%(9/18),94.44%(17/18)vs.66.67%(12/18)],and the differences were statistically significant(χ^(2)=4.71,P=0.034;χ^(2)=4.43,P=0.034).The incidence of diarrhea in the observation group was higher than that in the control group[55.56%(10/18)vs.16.67%(3/18),P=0.035].However,there were no statistically significant differences in the incidence of nausea,fatigue,and stomatitis between the 2 groups(P=1.000).The median progression-free survival(PFS)time in the observation group and the control group was 14.38 months and 12.08 months,respectively,and the difference in PFS was statistically significant(P=0.040).The median overall survival(OS)time in the observation group and the control group was 15.78 months and 11.19 months,respectively,and the difference in OS was statistically significant(P=0.034).ConclusionsRadiotherapy combined with pyrotinib is effective in the trea

关 键 词：乳腺肿瘤 肿瘤转移 人表皮生长因子受体2 药物疗法 联合 吡咯替尼 

分 类 号：R737.9[医药卫生—肿瘤]